ZIMLAB Q2 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Zim Laboratories reported Q2 FY27 total operating income of Rs. 1,054M (+19% YoY, +12% QoQ) with EBITDA of Rs. 77M (7.3% margin, +365 bps QoQ) but net loss of Rs. 21M. H1 FY27 revenue grew 24% YoY to Rs. 1,996M, though EBITDA margin declined to 5.6% from 8.4%. Key drivers were NIP/OTF revenue up 84% YoY to Rs. 149M (14% of revenue) and new market expansion. EU-GMP recertification is the critical catalyst, with management expecting CAPA acceptance within days and certificate in 1-1.5 months. FY27 revenue target is Rs. 415-420 cr without EU, Rs. 450-460 cr with EU orders. Long-term target is 20-25% CAGR to ~Rs. 700 cr with 18-20% EBITDA margin by FY30, with no significant CAPEX needed.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong sequential recovery, new product momentum, TGA Australia approval, and cost rationalization initiatives, with a cautiously optimistic outlook for H2.
- Q&A Session: Neutral — Analysts pressed on EU-GMP timeline, margin recovery, and growth visibility; management provided direct answers but acknowledged external uncertainties and declined to give precise FY30 guidance, maintaining an 18-20% EBITDA target.
Revenue Growth Drivers
- NIP and OTF revenue growth (84% YoY)
- New market expansion (LATAM, MENA, Africa, SE Asia)
- Legacy pharmaceutical business growth 16% YoY
Growth vs Margin Focus
Management emphasized topline growth (20-25% CAGR target) while also focusing on cost optimization and operating leverage to improve EBITDA margins to 18-20% at Rs. 700 cr revenue. They explicitly stated they don't want to be too optimistic on margins until EU stream is stable, indicating balanced a
About Zim Laboratories Limited
Zim Laboratories Limited (ZIMLAB) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.